Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.41 |
| ▸ | KDR | P35968 | 9/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.41 |
| ▸ | CSF1R | P07333 | 2/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7160706 | 0.81 | MALT1 (0.45) | KDRCSF1RNUDT1ENPP1 | |
| SCHEMBL31554483 | 0.81 | MALT1 (0.45) | KDRCSF1RNUDT1ENPP1 | |
| SCHEMBL31701647 | 0.71 | ATR (0.44) | KDR | |
| SCHEMBL21375591 | 0.69 | PDGFRA (0.55) | METKDRPDGFRAKIT | |
| SCHEMBL3631578 | 0.68 | ATR (0.44) | KDR | |
| SCHEMBL27700692 | 0.68 | HPGDS (0.42) | KDRCSF1R | |
| SCHEMBL5747725 | 0.68 | MALT1 (0.46) | — | |
| SCHEMBL6345971 | 0.68 | EHMT2 (0.53) | KDR | |
| SCHEMBL25631419 | 0.67 | MALT1 (0.49) | METKDRCSF1RNUDT1 | |
| SCHEMBL20176898 | 0.67 | NPC1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210177828-A1 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177828-A1 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | CSF1R, CSF3R, FLT3 | MET 107/4885KDR 165/4885PDGFRA 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.